BioNTech SE - ADR vs Star Bulk Carriers Corp — how do they compare? BioNTech SE - ADR trades at $90.13 (market cap $22.86B), while Star Bulk Carriers Corp trades at $26.32 (market cap $2.96B). The key difference: BioNTech SE - ADR is far larger — about 7.7× Star Bulk Carriers Corp's market cap, and Star Bulk Carriers Corp pays a 3.88% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| BNTX | SBLK | |
|---|---|---|
Market Cap | $22.86B | $2.96B |
Sector | Health | Industrials |
52-Week High | $119.34 | $28.21 |
52-Week Low | $83.89 | $16.79 |
Enterprise Value | $6.53B | $3.66B |
Dividend Yield | — | 3.88% |
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $90.07, down 1.55% today, amid a bearish technical signal and declining revenue trends. The company reported a net loss of $1.14 billion in 2025, with profitability metrics negative, though it maintains a strong cash position of $16.78 billion. Recent news highlights restructuring efforts, including site closures and a $1 billion share buyback, as it pivots focus to oncology pipeline development following reduced COVID-19 vaccine demand.
The outlook remains challenging with persistent losses and competitive pressures, but analyst consensus is bullish with a $129.67 price target. Key risks include execution of the oncology strategy and revenue volatility. The stock's current valuation reflects uncertainty, offering potential upside if pipeline milestones are met, but investors face significant operational and market headwinds.
Star Bulk Carriers (SBLK) trades at $26.54, up 0.72% with strong technical momentum and bullish moving average signals. The company demonstrates solid fundamentals with Q1 2026 earnings beating expectations at $0.56 EPS versus $0.475 expected, while maintaining a healthy 13.01% net income margin. Recent news highlights robust dry bulk rates supporting potential double-digit dividend yields, with the company's modernizing fleet and opportunistic asset sales strengthening the balance sheet.
SBLK presents a compelling opportunity with strong cash flow generation and shareholder returns, though investors face risks from spot rate volatility and cyclical shipping demand. Wall Street maintains bullish sentiment with 14 buy ratings versus 2 sells, while technical indicators show potential resistance near $27 levels. The company's disciplined capital allocation and fleet renewal strategy provide upside potential if dry bulk markets remain favorable.
Trailing returns across standard periods
Latest headlines on both assets
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →Star Bulk Carriers Corp. is a global shipping company specializing in the seaborne transportation of dry bulk commodities. The company owns and operates a large fleet of bulk carriers, primarily transporting major commodities such as iron ore, coal, and grain. SBLK focuses on the Capesize, Post Panamax, and Kamsarmax vessel segments, providing critical logistical services to commodity producers and consumers worldwide.
Read more on SBLK →